Skip to main content
BioMaxima S.A. logo

BioMaxima S.A. — Investor Relations & Filings

Ticker · BMX ISIN · PLBIOMX00015 LEI · 2594007GAALFMXP4YB89 WAR Manufacturing
Open in API
Filings indexed 617 across all filing types
Latest filing 2023-10-20 Regulatory Filings
Country PL Poland
Listing WAR BMX

About BioMaxima S.A.

https://www.biomaxima.com/

BioMaxima S.A. is a manufacturer specializing in in-vitro diagnostics. The company's primary activities include the development and production of a wide range of products for laboratory diagnostics, with a focus on clinical microbiology. Key product categories include microbiological media, various diagnostic reagents, and specialized laboratory equipment. In addition to its manufacturing operations, BioMaxima also serves as a distributor for products from other global diagnostics firms. The company is actively involved in product innovation, including the development of Minimum Inhibitory Concentration (MIC) tests for antibiotic susceptibility testing.

Recent filings

Filing Released Lang Actions
Informacja o pozytywnej ocenie wniosku o dofinansowanie w kwocie 4 824 793,35 zł - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the management board of BioMaxima SA (Zarząd BioMaxima SA informuje) regarding receiving a positive evaluation from the Polish Agency for Enterprise Development (Polska Agencja Rozwoju Przedsiębiorczości) for a specific R&D project under the SMART Path action. It details the grant amount (4,824,793.35 PLN) and the project's scope (developing real-time qPCR and LAMP test kits for Salmonella and Listeria). This announcement concerns fundraising, financing activities (receiving a grant/subsidy), and capital structure/development plans related to R&D. This aligns best with the 'Capital/Financing Update' category (CAP), as it is a significant funding event for the company's operations and expansion, rather than a general regulatory filing (RNS) or a management change (MANG). Given the document's content focuses entirely on securing significant external funding for a project, CAP is the most appropriate classification.
2023-10-20 Polish
Zawiadomienie
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakcjach, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction(s) referred to in Article 19(1) of the MAR Regulation). This regulation (MAR - Market Abuse Regulation) mandates disclosures regarding transactions conducted by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. The content details a 'Nabycie' (Acquisition) of shares by 'TriCar Services Ltd.', which is closely associated with a member of the Supervisory Board ('Andrzej Mikosz'). This directly corresponds to the definition of Director's Dealing (insider trades). Matching this to the provided definitions, 'Director's Dealing (Code: DIRS)' is the most appropriate classification.
2023-10-09 Polish
Zawiadomienie od osoby zobowiązanej - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document text is extremely short (124 characters) and states that the Management Board received a notification from a Shareholder, which is attached to the current report ('stanowi załącznik do niniejszego raportu'). This structure strongly suggests an announcement about the availability of an attached document, rather than the content of the document itself. Since the content is a notification from a shareholder (likely regarding share ownership changes), the most appropriate classification based on the 'MENU VS MEAL' rule is a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the context of shareholder notification, it is likely related to shareholding changes (MRQ), but the text itself is purely an announcement of an attachment. I will classify it as RNS as it is a general regulatory announcement about receiving and attaching a shareholder notification, which is a common pattern for miscellaneous regulatory updates not fitting a specific report type, or RPA if it's announcing the publication of the full filing. Since it's a notification received and attached, RNS is a safer general regulatory fallback, although MRQ might be the underlying subject matter. Given the brevity and focus on the attachment, RPA or RNS is best. I will choose RNS as the general regulatory announcement category for this brief notice.
2023-10-09 Polish
Raport z przeglądu sprawozdania jednostkowego
Audit Report / Information Classification · 99% confidence The document is explicitly titled in Polish as "RAPORT NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z PRZEGLĄDU ŚRÓDROCZNEGO SKRÓCONEGO SPRAWOZDANIA FINANSOWEGO" (Independent Auditor's Review Report on the Interim Condensed Financial Statements) for the period ending June 30, 2023. This document contains the auditor's conclusion based on a review of interim financial statements. This directly matches the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinguishing it from a full Annual Report (10-K) or a Quarterly Report (IR) which would contain the statements themselves, not just the review report on them. The content focuses entirely on the scope and conclusion of the review process. H1 2023
2023-09-29 Polish
Raport z przeglądu sprawozdania skonsolidowanego
Audit Report / Information Classification · 99% confidence The document is titled 'RAPORT NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z PRZEGLĄDU ŚRÓDROCZNEGO SKRÓCONEGO SKONSOLIDOWANEGO SPRAWOZDANIA FINANSOWEGO' (Independent Auditor's Report on the Review of the Interim Condensed Consolidated Financial Statements) for the period ending June 30, 2023. This explicitly identifies the document as a formal report issued by an auditor following a review of interim financial statements. This aligns perfectly with the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinguishing it from a full Annual Report (10-K) or a comprehensive Interim Report (IR) prepared by the company itself. The document contains the auditor's conclusion ('Wniosek') based on the review procedures. H1 2023
2023-09-29 Polish
Sprawozdanie Zarządu
Interim / Quarterly Report Classification · 95% confidence The document is a 'Sprawozdanie Zarządu z działalności' (Management Board Report on Activities) for the first half of 2023 for BioMaxima S.A. It covers business operations, financial situation, corporate governance, and management commentary for the interim period. It is a comprehensive report detailing the company's performance and outlook, fitting the definition of an Interim/Quarterly Report (IR) as it provides substantive analysis and management discussion for a period shorter than a full fiscal year. H1 2023
2023-09-29 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.